Gingivitis, Inflamed Gums, Probiotics
Conditions
Brief summary
Objectives: This study investigates the effects of daily consumption of probiotic ayran drink on gingival inflammation and the development of experimental gingivitis. Methods: A total of 54volunteer students were included in the present randomized, double-blind, placebo-controlled trial.The participants were divided randomly into two groups; The Control group consisted of 27 participants who consumed placebo ayran, while the 27 participants of the Test group consumed probiotic ayran (containing Lactobacillus acidophilus and Bifidobacterium bifidum) for 42 days twice a day.After 42 days, mechanical plaque control was interrupted for 5 days. The clinical parameters of gingivitis; Plaque index (PI), gingival index (GI), probing bleeding (BOP), probing depth (PPD) were recorded at baseline, day 42 (beginning of experimental gingivitis) and day 47 (the end of experimental gingivitis). At the same time points, gingival crevicular fluid had been collected for analysis of matrix metalloproteinase - 8 (MMP-8).
Detailed description
The most used and studied probiotics in the periodontal literature are lactobacillus and bifidobacterium. The current study aims to observe the effects of daily ayran consumption containing a probiotic combination of Lactobacillus acidophilus and Bifidobacterium bifidum on plaque development and gingival inflammation in an experimental gingivitis model of healthy individuals. The null hypothesis of this study using of probiotics has no additional benefit for periodontal health. This study evaluates the effects of daily consumption of ayran containing a probiotic combination of Lactobacillus Acidophilus and Bifidobacterium Bifidum on plaque development and gingival status in healthy individuals with experimental gingivitis.
Interventions
The test group has received probiotic ayran drink for 6 weeks
The control group has received placebo ayran drink for 6 weeks
Sponsors
Study design
Eligibility
Inclusion criteria
* Systemic healthy * Subjects with gingivitis defined as a BOP sites ≥ 10% and PD ≤ 3 mm * No radiographic bone loss * Non-smoking participants
Exclusion criteria
* History of using antibiotics or anti-inflammatory drugs or probiotic preparations or food supplements in the last 6 months, * Undergoing orthodontic treatment, * Active carious lesions * Mouth breathing * History of allergy for milk or fermented milk products. * Taking medications affecting the gingiva and/or oral mucosa
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plaque index | Plaque index will be recorded at baseline, at day 42 and 47 | PI was scored from 0 to 5 according to the color change obtained with the Mira-2 solution |
| Gingival index | Gingival index will be recorded at baseline, at day 42 and 47 | GI is graded by visual assessment and mechanical stimulation of the gingival tissues, scoring the gingival condition according to the criteria |
| Bleeding on probing | BOP will be recorded at baseline, at day 42 and 47 | The probing bleeding (BOP) index was determined by the presence/absence of bleeding ≈30 seconds after probing |
Countries
Turkey (Türkiye)